FDA ties any mifepristone restrictions to a safety report due by March 2027

The FDA described its study as a screen. The agency said it is using a "statistical data mining method" to discover "unknown safety concerns" that may exist with mifepristone ^[6]. The data come from an electronic database of medical injury and drug side-effect reports, drawn from major insurers and health networks ^[7].

I'd expect a method built to find unknown concerns to turn up candidates for follow-up. The March report is worth reading for how it tests them. A pattern in injury records can reflect the drug, or it can reflect the health and circumstances of the people taking it, and a screen on its own does not separate the two. The account of the filing does not describe the comparison groups, or the threshold the agency will use before it treats a pattern as a real signal.

The calendar leaves limited time for that testing. About three months separate the study's mid-December finish from the report's deadline of "no later than March 2027" ^[18]. March is the latest date the agency gave, so the report could come sooner ^[5]. Only after the report will the FDA decide whether to impose new restrictions or other changes on the drug's use ^[5].

The screen is being run on a drug with a long record. Mifepristone was first approved in 2000 ^[8], 26 years before this filing ^[19]. Over that time the agency has repeatedly reaffirmed its safety and effectiveness and eased a number of restrictions, including dropping the requirement that it be dispensed in person ^[9]. Combined with misoprostol, it is the most common form of abortion in the U.S. ^[10].

Anti-abortion groups and their congressional allies have pressed the administration to take another look at the pill since President Donald Trump's return to the White House ^[11]. Most of their effort has gone into a 2021 decision allowing doctors to prescribe the drug online and send it by mail during COVID-19, which was made permanent under President Joe Biden in 2023 ^[12].

Gavin Oxley of Americans United for Life, an anti-abortion group, criticized the timeline as a lack of "true leadership" by Trump administration officials ^[13]. "The administration continues to find itself on the wrong side of women's health, clearly uninterested in mitigating the ongoing harms caused by the abortion pill," Oxley said ^[14].